Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$19.44
-1.7%		$24.67
$10.48
▼
$30.99
$1.29B-0.82601,095 shs299,724 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$32.49
+3.4%		$36.85
$13.30
▼
$43.73
$5.64B0.312.17 million shs1.84 million shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$54.58
-2.0%		$53.63
$44.12
▼
$78.48
$5.28B1.761.76 million shs617,301 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$304.29
+1.8%		$290.75
$166.10
▼
$326.63
$6.06B1.11268,926 shs172,134 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-3.47%-12.44%-19.53%-26.39%+76.76%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
+0.06%-5.30%-14.59%-17.54%+137.21%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-0.11%-2.84%-8.54%+1.42%-8.76%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+0.21%+5.04%+6.15%-1.50%+76.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$19.44
-1.7%		$24.67
$10.48
▼
$30.99
$1.29B-0.82601,095 shs299,724 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$32.49
+3.4%		$36.85
$13.30
▼
$43.73
$5.64B0.312.17 million shs1.84 million shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$54.58
-2.0%		$53.63
$44.12
▼
$78.48
$5.28B1.761.76 million shs617,301 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$304.29
+1.8%		$290.75
$166.10
▼
$326.63
$6.06B1.11268,926 shs172,134 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-3.47%-12.44%-19.53%-26.39%+76.76%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
+0.06%-5.30%-14.59%-17.54%+137.21%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-0.11%-2.84%-8.54%+1.42%-8.76%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+0.21%+5.04%+6.15%-1.50%+76.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2.75
Moderate Buy$32.6467.91% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.75
Moderate Buy$51.5658.68% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.59
Moderate Buy$67.9424.49% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$337.8911.04% Upside

Current Analyst Ratings Breakdown

Latest BCAX, LGND, CRSP, and COGT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$345.00
9/24/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$358.00
9/23/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$390.00 ➝ $397.00
9/22/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeEqual Weight
9/21/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
9/16/2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$55.00
9/15/2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$55.00
9/10/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$80.00
8/31/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$82.00
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$7.33 per shareN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$3.84 per shareN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,503.38N/AN/A$20.17 per share2.71
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$268.09M22.63$8.01 per share38.01$51.68 per share5.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$137.95M-$3.10N/AN/AN/AN/A-41.49%-38.59%11/9/2026 (Estimated)
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.16N/AN/AN/AN/A-84.47%-47.72%11/6/2026 (Estimated)
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.76N/AN/AN/A-3,368.72%-24.39%-18.25%11/9/2026 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$9.3532.5336.752.3967.88%20.06%11.68%11/5/2026 (Estimated)

Latest BCAX, LGND, CRSP, and COGT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.8198-$0.82-$0.0002-$0.82N/AN/A
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550-$0.52+$0.0350-$0.52$0.00 millionN/A
8/6/2026Q2 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.97$2.37+$0.40$2.22$61.30 million$63.69 million
8/3/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.19-$0.94+$0.25-$0.94$7.45 million$10.18 million
6/30/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$0.94N/A-$0.94N/A$10.18 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
11.59
11.59
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.48
13.57
13.57
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.34
17.85
17.85
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
1.16
31.18
30.96

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
13.80%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
10366.17 million57.04 millionN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
258173.52 million162.09 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
39396.69 million91.67 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4719.94 million18.82 millionOptionable

Recent News About These Companies

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Ligand Pharma (LGND) and Compass Therapeutics (CMPX)
September 25 at 9:28 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CMPX/pressreleases/4773213/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-ligand-pharma-lgnd-and-compass-therapeutics-cmpx/
Barclays Begins Coverage on Ligand Pharmaceuticals (NASDAQ:LGND)
September 25 at 8:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-barclays-begins-coverage-on-ligand-pharmaceuticals-nasdaq-lgnd-2026-09-25/
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Citigroup Analyst Says
September 25 at 1:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31046935
HC Wainwright Reiterates Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND)
September 24 at 12:23 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-hc-wainwright-reiterates-buy-rating-for-ligand-pharmaceuticals-nasdaq-lgnd-2026-09-24/
Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy
September 24 at 9:20 AM  |  rttnews.comhttps://www.rttnews.com/3693652/ligand-commits-upto-47-mln-to-avencell-cancer-cell-therapy.aspx
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell
September 24 at 9:20 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ligand-pharmaceuticals-invests-47-million-113521771.html
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
September 24 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368190/0/en/ligand-and-avencell-therapeutics-enter-financing-agreement-to-advance-pipeline-of-next-generation-car-t-therapies-for-up-to-47-million.html
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $397.00 Price Target at Citigroup
September 23 at 11:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ligand-pharmaceuticals-nasdaq-lgnd-given-new-39700-price-target-at-citigroup-2026-09-23/
Sydnexis sells EMEA royalty rights to Ligand for $23 million
September 23 at 3:04 AM  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Sydnexis+sells+EMEA+royalty+rights+to+Ligand+for+%2423+million/27088789.html
Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug
September 23 at 3:04 AM  |  rttnews.comhttps://www.rttnews.com/3692945/ligand-buys-royalty-rights-in-santen-s-ryjunea-eye-drug.aspx
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
September 23 at 3:04 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ligand-acquires-royalty-milestone-interest-110000068.html
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million
September 23 at 3:04 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ligand-pharmaceuticals-acquires-ryjunea-royalty-114706011.html
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million
September 22 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366139/0/en/ligand-acquires-royalty-and-milestone-interest-in-santen-s-ryjunea-from-sydnexis-for-23-million.html
Corient Private Wealth LP Boosts Stake in Ligand Pharmaceuticals Incorporated $LGND
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-boosts-stake-in-ligand-pharmaceuticals-incorporated-lgnd-2026-09-21/
Ligand Pharmaceuticals stock trades without a fresh catalyst
September 20, 2026  |  ad-hoc-news.deA
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold
September 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4948051-ligand-pharmaceuticals-the-multiple-is-the-whole-bet-hold?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947806-ligand-pharmaceuticals-owning-it-gives-you-a-stake-across-biotech?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Baird Financial Group Inc. Trims Holdings in Ligand Pharmaceuticals Incorporated $LGND
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-baird-financial-group-inc-trims-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-09-17/
Ligand Pharmaceuticals (NASDAQ:LGND) Director Martine Zimmermann Sells 1,200 Shares
September 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025238
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 1,200 Shares of Stock
September 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-09-15/
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $342,000.00 in Stock
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-ligand-pharmaceuticals-nasdaq-lgnd-director-sells-34200000-in-stock-2026-09-14/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$19.44 -0.34 (-1.73%)
As of 03:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$32.49 +1.06 (+3.37%)
As of 03:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$54.58 -1.13 (-2.02%)
As of 03:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$304.29 +5.25 (+1.75%)
As of 03:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas